SOURCE: The Medicines Company

The Medicines Company

September 09, 2010 18:38 ET

The Medicines Company Provides PTO Litigation Update

PARSIPPANY, NJ--(Marketwire - September 9, 2010) -  The Medicines Company (NASDAQ: MDCO) announced that, in a notice filed today with the U.S. District Court for the Eastern District of Virginia, the government stated that the U.S. Solicitor General has, at this time, elected against appeal of the Court's August 3 decision ordering the U.S. Patent and Trademark Office (PTO) to consider the Company's Angiomax® (bivalirudin) patent term extension application timely filed. 

The Medicines Company's lawsuit challenged the PTO's denial of the application for an extension of the term of U.S. Patent No. 5,196,404, the principal U.S. patent that covers Angiomax. 

On August 19, APP Pharmaceuticals, LLC filed a motion to intervene in this matter and a court hearing is scheduled for tomorrow regarding APP's motion.

A copy of the government's notice is posted on http://www.themedicinescompany.com.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company's website is www.themedicinescompany.com.

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the court order requiring the PTO to consider the Company's application to extend the term of the principal U.S. patent covering Angiomax timely filed is successful challenged, whether the Company is able to obtain or maintain patent protection for the intellectual property relating to the Company's products, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 9, 2010, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

Contact Information